Dalpiciclib and palbociclib all displayed a concentration-dependent inhibition of tumor growth in HNMM-PDC harboring CDK4 amplification, but there was no inhibitory effect on HNMM-PDC with CDK4 wild type cells (Fig. 1G,H). This evidence concerns the gene CDK4 and neoplasm.